ClinicalTrials.gg
Not yet recruitingNCT07770620Updated Aug 18, 2026

Effects of Face-to-Face Versus Telerehabilitation-Based Circuit Training in People With Multiple Sclerosis

An interventional study of Face-to-Face Circuit Training and Synchronous Telerehabilitation-Based Circuit Training in Multiple Sclerosis, sponsored by Istanbul University - Cerrahpasa. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa — 5 open to participants now, 6 under way, none of them phase 3. Multiple Sclerosis · Istanbul University - Cerrahpasa.

Planned enrollment
6th of 10
36 · median 38
Started
2026
with 2 others
No phase
10 of 16
4 open now
Registered
16th of 16
by date

Among the 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 10 with no phase, and was the 16th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Sclerosis by Istanbul University - Cerrahpasa, or all of them as a file.
02

Study summary

This randomized controlled study was planned to compare the effects of delivering the same exercise content face-to-face and through telerehabilitation in individuals diagnosed with multiple sclerosis. All participants will receive circuit training for 8 weeks. The program will consist of two sessions per week, each lasting approximately 60 minutes. Assessments will be performed before and after treatment. Participants will be divided into two groups according to the mode of delivery: face-to-face and telerehabilitation. Telerehabilitation sessions will be conducted synchronously (via live connection) twice a week.

The study population will consist of adults aged 18-65 years with a diagnosis of MS who attend Istanbul University-Cerrahpaşa Hospital. Individuals who meet the eligibility criteria will be included in the study on a voluntary basis after being informed about the study. Participants will be allocated to the groups using stratified randomization based on EDSS scores.

The circuit training program will consist of endurance-, resistance-, and balance-focused exercise components. The effects of the interventions will be evaluated in terms of walking endurance and speed, functional mobility, dynamic balance, lower-extremity functional muscle strength, perceived walking ability, fatigue, quality of life, and the physical and psychological impact of MS. All assessments will be performed before the intervention and at the end of the 8-week program.

Read the detailed description

Multiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination, and axonal loss in the central nervous system, affecting functions such as balance, walking, muscle strength, and fatigue, thereby reducing individuals' participation in activities and quality of life. Balance, coordination, strengthening, and aerobic exercise approaches are widely used in MS rehabilitation, and these methods are supported by a high level of evidence for improving functional capacity.

One method that allows these approaches to be combined and structured around functional tasks is circuit training, in which exercises are organized as consecutive stations with short rest intervals. Circuit training is defined as a comprehensive exercise model that targets endurance, balance, strength, and motor control components within the same session. Straudi et al. demonstrated that supervised and home-based task-oriented circuit training improved walking endurance and had positive effects on walking speed, functional mobility, fatigue, and muscle oxygen consumption. Doğan et al. reported that telerehabilitation- and virtual reality-supported circuit training improved trunk control, upper extremity function, and ataxia severity. In a meta-analysis conducted by Du et al., circuit training interventions were reported to have positive effects on balance, walking, fatigue, and quality of life in individuals with MS.

However, studies directly investigating circuit training in individuals with MS are limited. In recent years, telerehabilitation has emerged as a contemporary approach that provides access independent of distance; however, the need for further controlled studies to strengthen the level of evidence in MS has been emphasized.

The aim of this study is to investigate and compare the effects of an 8-week circuit training program delivered face-to-face and through synchronous telerehabilitation on walking capacity, functional mobility, lower-extremity muscle strength, fatigue, activities of daily living, and quality of life in individuals with MS.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis
  • circuit training
  • telerehabilitation
  • rehabilitation
  • technology
  • Physiotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple sclerosis Age between 18 and 65 years Expanded Disability Status Scale (EDSS) score between 2.0 and 5.5 (MMSE) score greater than 24 No relapse within the past 3 months Ability to walk at least 100 meters with or without an assistive device Willingness to participate in the study and provision of written

Exclusion criteria

Exclusion Criteria:

  • Botulinum toxin treatment for spasticity or a surgical procedure within the past 6 months Participation in a regular physiotherapy or rehabilitation program within the past 3 months Presence of a secondary neurological, orthopedic, or systemic disease that prevents independent standing and walking Presence of severe peripheral vestibular dysfunction Presence of a medical condition that may prevent participation in exercise Failure to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Face-to-Face

    Participants in this group will receive an 8-week circuit training program delivered face-to-face in a clinical setting. The program will be conducted twice a week, with each session lasting approximately 60 minutes, and will include endurance, resistance, and balance exercises.

    Behavioral: Face-to-Face Circuit Training

  • Experimental
    Telerehabilitation-Based

    Participants in this group will receive the same 8-week circuit training program through synchronous telerehabilitation. The program will be conducted twice a week through live online sessions, with each session lasting approximately 60 minutes, and will include endurance, resistance, and balance exercises.

    Behavioral: Synchronous Telerehabilitation-Based Circuit Training

Interventions

  • BehavioralFace-to-Face Circuit Training

    Participants will receive an 8-week circuit training program delivered face-to-face in a clinical setting. The program will be conducted twice a week, with each session lasting approximately 60 minutes. The circuit training program will include endurance, resistance, and balance exercises. Each exercise station will consist of 3 minutes of exercise followed by 2 minutes of rest. Participants will complete two circuits, with a 10-minute rest period between circuits.

  • BehavioralSynchronous Telerehabilitation-Based Circuit Training

    Participants will receive the same 8-week circuit training program through synchronous telerehabilitation. The program will be conducted twice a week through live online sessions, with each session lasting approximately 60 minutes. The circuit training program will include endurance, resistance, and balance exercises. Each exercise station will consist of 3 minutes of exercise followed by 2 minutes of rest. Participants will complete two circuits, with a 10-minute rest period between circuits.

06

What researchers measure

Primary outcomes

  1. Walking Endurance: 6-Minute Walk Test (6MWT)

    Walking endurance will be assessed using the 6-Minute Walk Test. During the test, participants will be instructed to walk as far as possible for 6 minutes along a predefined, level course. At the end of the test, the total distance covered will be recorded in meters, and this value will reflect the individual's functional walking capacity and endurance. Any assistive device used by the participant, the need for rest, and the development of symptoms during the test will also be recorded.

    Time frame: Baseline and post-intervention at Week 8

Secondary outcomes

  1. Walking Speed: Timed 25-Foot Walk Test (T25FW)

    Walking speed will be assessed using the Timed 25-Foot Walk Test. Participants will be instructed to walk a distance of 25 feet, approximately 7 meters, safely but as quickly as possible. The time required to complete the test will be recorded in seconds; a shorter completion time indicates better short-distance walking performance. This test will be used to objectively assess ambulation and lower-extremity function in individuals with MS.

    Time frame: Baseline and post-intervention at Week 8

  2. Functional Mobility: Timed Up and Go Test (TUG)

    Functional mobility will be assessed using the Timed Up and Go Test. The participant will begin in a seated position on a chair; upon command, the participant will stand up, walk a distance of 3 meters, turn around, return to the chair, and sit down. The time required to complete the test will be recorded in seconds. This test provides an integrated assessment of functional movements frequently used in daily life, including sit-to-stand, walking, turning, and sitting down.

    Time frame: Baseline and post-intervention at Week 8

  3. Dynamic Balance: Mini-Balance Evaluation Systems Test (Mini-BESTest)

    Dynamic balance will be assessed using the Mini-BESTest. The Mini-BESTest consists of tasks involving anticipatory postural control, reactive postural responses, sensory orientation, and dynamic gait. The participant's ability to use different balance strategies, generate postural responses, and maintain stability during movement will be assessed. Each item will be scored according to performance, and the total score will provide information about the level of dynamic balance.

    Time frame: Baseline and post-intervention at Week 8

  4. Lower-Extremity Functional Muscle Strength: Five Times Sit-to-Stand Test (5xSTS)

    Lower-extremity functional muscle strength will be assessed using the Five Times Sit-to-Stand Test. Participants will be instructed to stand up from and sit down on a standard chair five consecutive times, preferably without using their arms. The time required to complete the test will be recorded in seconds. A shorter completion time will indicate better lower-extremity functional muscle strength and functional transfer performance. Participants will be observed for safety during the test, and the use of an assistive device will be recorded if necessary.

    Time frame: Baseline and post-intervention at Week 8

  5. Patient-Perceived Impact on Walking Ability: Multiple Sclerosis Walking Scale-12 (MSWS-12)

    The patient-perceived impact on walking ability will be assessed using the MSWS-12. The scale consists of 12 items that assess the impact of MS on walking function based on patient-reported outcomes. Participants will rate the difficulties they have experienced while walking and the impact of these difficulties on their daily lives. Higher scores indicate a greater perceived limitation in walking due to MS.

    Time frame: Baseline and post-intervention at Week 8

  6. Fatigue: Modified Fatigue Impact Scale (MFIS)

    Fatigue will be assessed using the Modified Fatigue Impact Scale. The MFIS is a patient-reported measure that assesses the physical, cognitive, and psychosocial impact of fatigue on daily life. Participants will indicate the extent to which fatigue has affected their activities, cognitive functioning, social life, and overall functioning. Higher total scores indicate a greater impact of fatigue on daily life.

    Time frame: Baseline and post-intervention at Week 8

  7. Quality of Life: Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL)

    Quality of life will be assessed using the MusiQoL. The MusiQoL is a patient-reported measure developed to assess MS-specific health-related quality of life. The questionnaire evaluates different dimensions of quality of life, including activities of daily living, psychological well-being, symptoms, relationships with friends, family relationships, coping, relationship with the health care system, and the overall impact of the disease on the individual. Higher scores indicate better perceived quality of life.

    Time frame: Baseline and post-intervention at Week 8

  8. Physical and Psychological Impact of Multiple Sclerosis: Multiple Sclerosis Impact Scale-29 (MSIS-29)

    The physical and psychological impact of MS will be assessed using the MSIS-29. The scale consists of 29 items that assess the patient-reported impact of MS on daily life, physical functioning, mobility, emotional status, and overall well-being. The physical and psychological subscales can be evaluated separately. Higher total and subscale scores indicate a greater perceived impact of the disease on the individual.

    Time frame: Baseline and post-intervention at Week 8

07

Study locations

1 site
  • Bakırköy Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital
    Istanbul, Istanbul 34147, Turkey (Türkiye)
08

References and documents

Publications

  • Chisari C, Venturi M, Bertolucci F, Fanciullacci C, Rossi B. Benefits of an intensive task-oriented circuit training in Multiple Sclerosis patients with mild disability. NeuroRehabilitation. 2014;35(3):509-18. doi: 10.3233/NRE-141144. PubMed 25248447 ↗
  • Lehmann I, Thaler I, Luder G, Damm U, Walti C, Steinheimer S, Verra ML, Muri RM, Nyffeler T, Vanbellingen T, Kamm CP. Standardized, comprehensive, hospital-based circuit training in people with multiple sclerosis: results on feasibility, adherence and satisfaction of the training intervention. Eur J Phys Rehabil Med. 2020 Jun;56(3):279-285. doi: 10.23736/S1973-9087.20.06191-2. Epub 2020 Mar 30. PubMed 32225136 ↗
  • Ozden F, Ozkeskin M, Yuceyar N. The reliability and validity of the Turkish version of the multiple sclerosis impact scale-29. Turk J Med Sci. 2022 Aug;52(4):1216-1222. doi: 10.55730/1300-0144.5426. Epub 2022 Aug 10. PubMed 36326386 ↗
  • Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J; MusiQol study group. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008 Mar;14(2):219-30. doi: 10.1177/1352458507080733. Epub 2007 Oct 17. PubMed 17942521 ↗
  • Armutlu K, Keser I, Korkmaz N, Akbiyik DI, Sumbuloglu V, Guney Z, Karabudak R. Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients. J Neurol Sci. 2007 Apr 15;255(1-2):64-8. doi: 10.1016/j.jns.2007.01.073. Epub 2007 Mar 6. PubMed 17337007 ↗
  • Dib H, Tamam Y, Terzi M, Hobart J. Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale. Mult Scler J Exp Transl Clin. 2017 Sep 1;3(3):2055217317728740. doi: 10.1177/2055217317728740. eCollection 2017 Jul-Sep. PubMed 28975038 ↗
  • Moller AB, Bibby BM, Skjerbaek AG, Jensen E, Sorensen H, Stenager E, Dalgas U. Validity and variability of the 5-repetition sit-to-stand test in patients with multiple sclerosis. Disabil Rehabil. 2012;34(26):2251-8. doi: 10.3109/09638288.2012.683479. Epub 2012 May 22. PubMed 22612360 ↗
  • Dogruoz Karatekin B, Icagasioglu A, Pasin O. Validity, reliability and minimal detectable change of Mini-BESTest Turkish version in neurological disorders. Acta Neurol Belg. 2023 Aug;123(4):1519-1525. doi: 10.1007/s13760-023-02299-7. Epub 2023 Jun 16. PubMed 37326807 ↗
  • Sebastiao E, Sandroff BM, Learmonth YC, Motl RW. Validity of the Timed Up and Go Test as a Measure of Functional Mobility in Persons With Multiple Sclerosis. Arch Phys Med Rehabil. 2016 Jul;97(7):1072-7. doi: 10.1016/j.apmr.2015.12.031. Epub 2016 Mar 2. PubMed 26944709 ↗
  • Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):704-710. doi: 10.1177/1352458517690823. Epub 2017 Feb 16. PubMed 28206828 ↗
  • Wetzel JL, Fry DK, Pfalzer LA. Six-minute walk test for persons with mild or moderate disability from multiple sclerosis: performance and explanatory factors. Physiother Can. 2011 Spring;63(2):166-80. doi: 10.3138/ptc.2009-62. Epub 2011 Apr 13. PubMed 22379256 ↗
  • Cardini R, Corrini C, Bertoni R, Anastasi D, Cattaneo D, Gervasoni E. Exploring the effectiveness of circuit training rehabilitation on balance, gait, and fatigue in multiple sclerosis: a systematic review and meta-analysis. Physiotherapy. 2024 Dec;125:101413. doi: 10.1016/j.physio.2024.101413. Epub 2024 Jul 20. PubMed 39357272 ↗
  • Dogan M, Ayvat E, Kilinc M. Telerehabilitation versus virtual reality supported task-oriented circuit therapy on upper limbs and trunk functions in patients with multiple sclerosis: A randomized controlled study. Mult Scler Relat Disord. 2023 Mar;71:104558. doi: 10.1016/j.msard.2023.104558. Epub 2023 Feb 11. PubMed 36812718 ↗
  • Straudi S, De Marco G, Martinuzzi C, Baroni A, Lamberti N, Brondi L, Da Roit M, Pizzongolo LDM, Basaglia N, Manfredini F. Combining a supervised and home-based task-oriented circuit training improves walking endurance in patients with multiple sclerosis. The MS_TOCT randomized-controlled trial. Mult Scler Relat Disord. 2022 Apr;60:103721. doi: 10.1016/j.msard.2022.103721. Epub 2022 Mar 5. PubMed 35276451 ↗
  • Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024 Feb 23;103(8):e37297. doi: 10.1097/MD.0000000000037297. PubMed 38394496 ↗
  • Vanbellingen T, Kamm CP. Neurorehabilitation Topics in Patients with Multiple Sclerosis: From Outcome Measurements to Rehabilitation Interventions. Semin Neurol. 2016 Apr;36(2):196-202. doi: 10.1055/s-0036-1579694. Epub 2016 Apr 26. PubMed 27116726 ↗
  • Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001 Jun;14(3):271-8. doi: 10.1097/00019052-200106000-00003. PubMed 11371748 ↗

Individual participant data

Plan to share: No — There is currently no plan to share individual participant data (IPD) with other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 3 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 18, 2026
StartEst.
Sep 14, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 15, 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07770620
Responsible party
Adennur Tayboğa (Research Assistant, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Aug 18, 2026
Start date
Sep 14, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Aug 18, 2026

Study contacts

Yonca Zenginler Yazgan, PhD
Contact
y.zenginleryazgan@iuc.edu.tr
+905326006294
Adennur Tayboğa, BSc
Contact
adennurtayboga@gmail.com
+905369651764

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion